<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arrowhead Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc</link>
<description>Latest news and press releases for Arrowhead Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 10:39:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arrowhead-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835484878dffbe2df0e3c1e.webp</url>
<title>Arrowhead Pharmaceuticals Inc</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc</link>
</image>
<item>
<title>Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-positive-chmp-opinion-recommending-approval-of-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-positive-chmp-opinion-recommending-approval-of-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs-in-europe</guid>
<pubDate>Fri, 24 Apr 2026 10:39:00 GMT</pubDate>
<description>PASADENA, Calif., April 24, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion, recommending the approval of REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS remains widely underdiagnosed and affects an estimated 1 to 1</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-second-quarter-results</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-second-quarter-results</guid>
<pubDate>Mon, 20 Apr 2026 20:01:00 GMT</pubDate>
<description>PASADENA, Calif., April 20, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-presents-new-long-term-efficacy-and-safety-data-for-plozasiran-across-a-spectrum-of-hypertriglyceridemia-at-the-american-college-of-cardiologys-75th-annual-scientific-session-and-expo</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-presents-new-long-term-efficacy-and-safety-data-for-plozasiran-across-a-spectrum-of-hypertriglyceridemia-at-the-american-college-of-cardiologys-75th-annual-scientific-session-and-expo</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-participate-in-upcoming-march-2026-events</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-participate-in-upcoming-march-2026-events</guid>
<pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., February 24, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-fiscal-2026-210500386</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-fiscal-2026-210500386</guid>
<pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
<description>PASADENA, Calif., February 05, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results.</description>
</item>
<item>
<title>Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/ciena-set-to-join-sandp-500-arrowhead-pharmaceuticals-to-join-sandp-midcap-400-adt-and-onespaworld-holdings-to-join-sandp-smallcap-600-2</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/ciena-set-to-join-sandp-500-arrowhead-pharmaceuticals-to-join-sandp-midcap-400-adt-and-onespaworld-holdings-to-join-sandp-smallcap-600-2</guid>
<pubDate>Wed, 04 Feb 2026 23:15:00 GMT</pubDate>
<description>S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-123000874</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-123000874</guid>
<pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-webcast-fiscal-2026-213000415</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-webcast-fiscal-2026-213000415</guid>
<pubDate>Tue, 20 Jan 2026 21:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 20, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 first quarter ended December 31, 2026.</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-prices-upsized-offerings-040500924</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-prices-upsized-offerings-040500924</guid>
<pubDate>Thu, 08 Jan 2026 04:05:00 GMT</pubDate>
<description>PASADENA, Calif., January 08, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the "notes") and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-nmpa-approval-123000759</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-nmpa-approval-123000759</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 07, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-proposed-offerings-231400976</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-proposed-offerings-231400976</guid>
<pubDate>Tue, 06 Jan 2026 23:14:00 GMT</pubDate>
<description>PASADENA, Calif., January 06, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes") and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-interim-clinical-123000690</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-interim-clinical-123000690</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 06, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO...</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-health-canada-approval-redemplotm-plozasiran</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-health-canada-approval-redemplotm-plozasiran</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>– REDEMPLO is the first and only Health Canada-approved siRNA medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS –</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-participate-upcoming-january-2026-events-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-participate-upcoming-january-2026-events-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-0</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-0</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-aro-mapt-treatment-alzheimers</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-aro-mapt-treatment-alzheimers</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-plozasiran</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-plozasiran</guid>
<pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
<description>PALISADE Phase 3 results demonstrate plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83% in</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-participate-upcoming-december-2025-conferences-2025-12-01</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-participate-upcoming-december-2025-conferences-2025-12-01</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>- Conference Call and Webcast Today, November 25, 2025, at 4:30 p.m. ET PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-earns-200-million-milestone-payment-sarepta-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-earns-200-million-milestone-payment-sarepta-therapeutics</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from</description>
</item>
</channel>
</rss>